Screening Probiotics for Anti- and Investigating the Effect of Probiotics on Patients with Infection.

Probiotics are natural microbial agents with beneficial properties such as bacteriostatic and anti-infective properties. Q21, Q25 and QA85, were isolated from the Chinese specialty fermented food "Jiangshui" and proved to be highly resistant to ( < 0.0001). In vitro results showed that Q21, Q25 and QA85 strongly inhibited and could specifically co-aggregate in vitro (more than 56%). Strains have the potential to adhere to cells and hinder colonization ( < 0.0001). To assess the anti- efficacy of strains in vivo, volunteers were recruited and a self-controlled study of probiotic intervention was conducted. Compared to pre-probiotics, volunteers who took Q21, Q25 and QA85 for 1 month showed significant improvement in discomfort, a significant reduction in GSRS scores ( < 0.05), and modulation of inflammatory response ( < 0.05). Q21, Q25 and QA85 resulted in a decreasing trend of load in volunteers (454.30 ± 327.00 vs. 328.35 ± 237.19, = 0.06). However, the strains were not significantly effective in modulating the imbalance of the gut microbiota caused by infection. In addition, strains affect metabolic pathways by increasing the levels of O-Phosphoethanolamine and other related metabolites, which may ameliorate associated symptoms. Therefore, Q21, Q25 and QA85 can be regarded as a candidate probiotic preparation that exerts direct or indirect anti- effects by inhibiting activity and colonization, reducing inflammation and discomfort, maintaining homeostasis in the internal environment, affecting the metabolic pathways and repairing the body barrier. They can play a role in relieving infection.